Products
Pre-made Camidanlumab Tesirine benchmark antibody (Whole mAb ADC, anti-IL2RA therapeutic antibody, Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-768
Pre-made Camidanlumab Tesirine benchmark antibody (Whole mAb ADC, anti-IL2RA therapeutic antibody, Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Camidanlumab tesirine (Cami-T or ADCT-31) is an antibody-drug conjugate (ADC) composed of a human antibody that binds to the protein CD25, conjugated to a pyrrolobenzodiazepine dimer toxin.
The experimental drug, developed by ADC Therapeutics is being tested in clinical trials for the treatment of B-cell Hodgkin's lymphoma (HL) and non-Hodgkin lymphoma (NHL), and for the treatment of B-cell acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-768-1mg | 1mg | Inquiry | ||
| GMP-Bios-INN-768-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-768-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-768-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Camidanlumab Tesirine Biosimilar, Whole Mab Adc, Anti-Il2Ra Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody Drug Conjugate |
| INN Name | Camidanlumab Tesirine |
| Target | IL2RA |
| Format | Whole mAb ADC |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Genmab A/S (Copenhagen Denmark) / ADC Therapeutics (Epalinges Switzerland) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
